©2025 Stanford Medicine
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Trial ID: NCT03994601
Purpose
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Official Title
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Stanford Investigator(s)
Thomas Holden
Clinical Assistant Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
* Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies
Exclusion Criteria:
* Active, known or suspected autoimmune disease
* Active malignancy requiring concurrent intervention
* Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded
Other protocol-defined inclusion/exclusion criteria apply
Intervention(s):
drug: BMS-986288
drug: Nivolumab
drug: Regorafenib
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Flordeliza Mendoza
650-724-2056